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The functional avidity is determined by exposing T-cell populations in vitro to diﬀerent amounts of cognate antigen. T-cells with
high functional avidity respond to low antigen doses. This in vitro measure is thought to correlate well with the in vivo eﬀector
capacity of T-cells. We here present the multifaceted factors determining and influencing the functional avidity of T-cells. We
outline how changes in the functional avidity can occur over the course of an infection. This process, known as avidity maturation,
can occur despite the fact that T-cells express a fixed TCR. Furthermore, examples are provided illustrating the importance of
generating T-cell populations that exhibit a high functional avidity when responding to an infection or tumors. Furthermore, we
discuss whether criteria based on which we evaluate an eﬀective T-cell response to acute infections can also be applied to chronic
infections such as HIV. Finally, we also focus on observations that high-avidity T-cells show higher signs of exhaustion and facilitate
the emergence of virus escape variants. The review summarizes our current understanding of how this may occur as well as how
T-cells of diﬀerent functional avidity contribute to antiviral and anti-tumor immunity. Enhancing our knowledge in this field is
relevant for tumor immunotherapy and vaccines design.
1. Introduction
CD8 T cells play a critical role in antiviral immunity, and a
large number of studies in both human and mice indicate
that antigen-specific CD8 T cells are directly involved in
not only the control of viral replication, but also tumor
growth [1–25]. Especially CD8 T-cell immunity against
HIV replication, and thus the prevention of the disease
progression, is well documented. This is primarily based
on the following observations: (a) depleting CD8 T cells
in the macaque model of AIDS leads to a loss of control
of virus replication [4, 5, 26], (b) HIV-specific T-cell
responses can be detected in previously virus exposed but
presently uninfected individuals [27–30], and (c) a higher
numbers of polyfunctional T cells are found in individuals
with nonprogressive infection or in the so-called “elite
controllers” [9–11], although there is a long-term debate as
to whether this is a cause or a consequence of viral control
[31]. Polyfunctional T cells characteristically show high IL-
2 expression and strong ability to upregulate granzyme B
and perforin. They have a high proliferative capacity and are
superior in controlling HIV infection. Furthermore, it has
been demonstrated by the whole genome analyses that HLA
class I alleles are the genetic factors most strongly associated
with nonprogressive infection [8, 15–22, 32, 33].
The aforementioned polyfunctionality is a well-
established important indicator for the ability of T cells
to control a virus infection. However, this parameter does
not reflect the ability of how a T-cell or a population
of T cells responds to a specific antigen. Instead, the
polyfunctionality is usually assessed upon exposing T cells
to peptide-MHC [pMHC] ligands at close to saturating
concentration. In this situation, it can be that T cells show
similar cytokine response patterns, although T cells might
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respond significantly diﬀerent upon exposure to limited or
physiologically relevant amounts of a ligand in vivo and in
vitro.
In contrast, the functional avidity is a biological measure
that describes how well a T-cell responds in vitro to a
given concentration of a ligand. By definition, T cells with
high functional avidity respond in in vitro tests to very
low antigen doses, while T cells of lower functional avidity
require higher amounts of antigen before they mount an
immune response similar to that of high-avidity T cells.
The functional avidity can be considered as a quantitative
determinant of the activation threshold of a T-cell clone.
In vivo, T cells of high and low avidity are exposed
to similar antigen doses, but numerous correlations exist
between the functional avidity and the eﬀectiveness of an
antiviral immune response, some of which will be discussed
later in this paper. Of note, ex vivo studies have shown
that distinct T-cell functions (e.g., proliferation, cytokines
production, etc.) are triggered with diﬀerent thresholds [34–
37].
The purpose of this paper is to provide information
on what distinguishes the functional avidity from other
parameters used to describe the ability of T cells to recognize
antigen and to summarize the known factors that determine
the functional avidity of T cells as well as the functional
avidity maturation of a T-cell population. The latter refers
to increases of the overall functional avidity with which a
polyclonal population responds to antigen. Moreover, we
suggest that combining functional avidity assessment and
polyfunctional analysis might lead to better predictions
concerning the ability of a T-cell population to control a
chronic infection than when both tests are independently
performed. Finally, we will critically discuss the general
consensus that high-avidity CD8 T-cell responses are always
better in controlling virus infections by presenting evidence
that this might not be the case in chronic infections,
particularly during HIV infection.
2. Factors Impacting the Functional Avidity of
a T-Cell Clone
The functional avidity inversely correlates with the antigen
dose that is needed to trigger a T-cell response. It is
determined by ex vivo quantification of biological functions
such as IFN-γ production, cytotoxic activity (ability to lyse
target cells), or proliferation. The concentration needed to
induce a half-maximum response (EC50) is often used to
describe the functional avidity of T cells. In particular, it
can be used to describe how monoclonal but also antigen-
specific polyclonal T-cell populations respond to antigen
stimulation.
The functional avidity of a T-cell clone (Figure 1) is
primarily impacted by (a) the aﬃnity of the TCR for the
pMHC-complex, that is, the strength of the interaction
between the TCR and pMHC [38, 39], (b) expression levels
of the TCR and the CD4 or CD8 coreceptors, and (c) the
distribution and composition of signaling molecules [40, 41]
as well as expression levels of molecules that attenuate T-cell
function and TCR signaling.
2.1. Aﬃnity, Avidity, and Functional Avidity of a T-Cell Clone.
The terms aﬃnity, avidity, and functional avidity are often
incorrectly interchangeably used. The TCR aﬃnity (Figure 1)
refers to the physical strength of the monomeric interaction
between the TCR and a pMHC-complex [42, 43]. The
dissociation constant (KD) for diﬀerent pMHC-TCR pairs
have been determined by surface plasmon resonance [44].
Several reports indicate that a lower KD and thus a stronger
interaction lead to a better T-cell response [45, 46]. Another
parameter that has been shown to influence the T-cell
response eﬃcacy is the half-life (t1/2) value of the interaction
between the TCR and the pMHC-complex; longer t1/2 times
also result in more potent T-cell stimulation [45, 47, 48]. It
still remains controversial which of these two parameters, the
KD or the t1/2 value, oﬀers a better prediction of how T cells
respond to antigen stimulation [48]. Low KD values result
from slow oﬀ-rates and/or rapid on-rates. Thus, pMHC-TCR
interactions, which have a long t1/2 time, usually also show
a low KD value. This relationship may in parts explain why
both KD and the t1/2 time have been reported to correlate
with the eﬃciency of T-cell activation. However, both low
KD and long t1/2 values are thought to permit completion
of intracellular signaling cascades leading to T-cell activation
[42, 49].
However, a clean biochemical determination of KD values
and t1/2 times is rather complicated, and it requires the
availability of soluble pMHC-complexes and a soluble form
of the TCR. Moreover, it needs to be considered that the
binding kinetics can significantly vary depending on whether
the interaction is measured with soluble or membrane-
bound ligands [50]. Alternatively, a more practical but less
precise way to assess the strength of pMHC-TCR interaction
is to stain living T cells with pMHC-multimers. Binding
kinetics can then be determined by measuring fluorescent
intensity of cell-surface bound multimers [51–53]. As the
latter involves binding of a ligand via multiple interactions
(i.e., the pMHC-multimers bind to more than one TCR),
such measurements are best described by the term avidity,
which is normally used to refer to the strength of multimeric
receptor-ligand engagement (Figure 1).
In contrast to the physical parameters aﬃnity and avidity,
the functional avidity describes how well a T-cell responds
to antigens. Though all of the three parameters correlate in
most cases, that is, high-aﬃnity T cells often have a high
functional avidity, this does not need to be the case. There are
several factors besides the antigen recognition ability of the
TCR that can impact the T-cell response. In principle, T cells
could express a high-aﬃnity TCR, but due to other factors,
for example, inhibitory molecules, it might show a very
weak response to antigen stimulation. Thus, determining the
functional avidity is not only often more practical, but is
also the only one out of the three parameters that actually
describes the functional outcome of the stimulation.
Notably, the level of TCR expression impacts the func-
tional avidity. Even though T cells are functional when they
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Figure 1: Schematic representation, definition, technique of measurement and readout of TCR aﬃnity and functional avidity.
express very little TCR, it has been shown that reduced
expression levels go along with decreased ability to respond
to antigen [54]. T cells with reduced TCR expression levels
are impaired in their proliferative capacity and in their ability
to secrete IL-2 and IFN-γ [55].
2.2. Coreceptor Expression Impacts the Functional Avidity
of a T-Cell Clone. CD4 and CD8 coreceptors bind to the
MHC classes II and I, respectively [56], and stabilize the
pMHC-TCR interaction. This is for instance illustrated by
the fact that pMHC-multimers bearing a mutation in the
CD8 binding site bind less eﬃciently to T cells [57], and
this is particularly prominent when a TCR binds with low-
aﬃnity to a pMHC-complex [58–60]. The importance of the
coreceptor engagement for pMHC-binding to the TCR is also
underlined by observations that antibodies against the CD8
coreceptor can decrease or block the extent to which pMHC-
multimers bind to a TCR. There are even antibody clones
enhancing the binding [61]. This might occur by inducing a
conformation that facilitates better binding of the coreceptor
to the MHC. This antibody enhancement or blockade is
even more critical when a TCR engages a low-aﬃnity ligand
[61]. Moreover, coreceptor engagement supports TCR signal
transduction by bringing Lck in close proximity to the
TCR complex [62, 63]. Reducing this coreceptor engagement
of Lck lowers the TCR sensitivity to antigen stimulation
and thus decreases induction of eﬀector function [39, 64].
However, the enhancement of the coreceptor MHC binding
is more critical for low than high-aﬃnity T-cell clones.
Thus, high-aﬃnity pMHC-TCR interactions are in contrast
to low-aﬃnity binding characterized by a relative CD8-
independence for both T-cell proliferation and cytotoxicity
as well as for multimer binding [57, 58, 60].
The aforementioned observations indicate how critically
the presence or absence of the coreceptor impacts the ability
of T cells to respond to a pMHC-complex. In addition,
several examples indicate the extent to which variations
in coreceptor expression levels or binding ability to MHC
molecules impact T-cell function. In mice, downregulation
of CD8 expression and reduced ability of T cells to respond
to antigen have been seen following Listeria monocytogenes or
Vaccinia virus infection [65]. Moreover, there is a polymor-
phism in the α3 domain of the HLA-A∗68 molecule resulting
in weak binding of the CD8 coreceptor to the MHC. When
the HLA-A∗68 sequence is artificially altered to restore CD8
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binding, then this altered molecule is recognized by TCRs
that fail to respond to normal HLA-A∗68. Thus, restoring
coreceptor engagement rescues cytokine production and T-
cell proliferation, even though the pMHC-TCR interaction
itself remains unchanged [66, 67]. Moreover, self-antigen-
specific T cells can downregulate CD8 expression to reduce
their functional avidity and thereby their autoreactive poten-
tial [68].
2.3. Alterations in TCR Signaling Can Impact the Functional
Avidity. TCR signaling is initiated when Lck (Src family
tyrosine kinase) phosphorylates immunoreceptor tyrosine-
based activation motifs (ITAM) within the CD3ζ molecule.
This provides a docking site for ZAP-70, which in turn gets
phosphorylated by Lck [69]. Activated ZAP-70 leads to the
recruitment and phosphorylation of linker for activation of
T-cell (LAT) and SH2-domain-containing leukocyte protein
of 76 kDa (SLP-76). This initiates a signaling cascade that
leads to Ca2+ mobilization as well as to the activation of the
mitogen-activated protein kinase (MAPK) signaling pathway
[70, 71].
Diﬀerent lines of evidence indicate that T cells can adjust
or tune the sensitivity of their signaling apparatus indicating
that functional avidity is not fixed [72]. In the thymus,
TCR-signaling sensitivity is thought to be augmented by
a micro RNA (miR181a), and this occurs via targeting
multiple phosphatases that otherwise inhibit the TCR signal
[73, 74]. This goes along with observations that T cells
respond to ligands in the thymus to which they much less
eﬀectively respond in the periphery [75, 76]. Furthermore,
TCR signal transduction is thought to be fine tuned by
inhibitory molecules such as CD5 [77]. CD5 expression
levels presumably correlate with the strength with which a
T-cell clone responded to its positive selecting ligand [77].
CD5 is an immune-tyrosine-based inhibition motif-bearing
receptor that could antagonize overt TCR activation in
peripheral T cells [78] and has been shown to be involved in
peripheral tolerance by adjusting T-cell reactivity [79]. Along
those lines, higher antigen sensitivity is determined by the
superior ability of high-avidity T cells to achieve threshold
levels of CD3ζ phosphorylation through increasing the
amount of activated Lck [80, 81].
If and how these and other pathways impact the
functional avidity of T cells need to be better determined.
However, the ability of peripheral T cells to alter their
antigen reactivity has been reported. Deprivation fromMHC
molecules has been shown to increase CD4 T-cell reactivity
[82], but also the opposite eﬀect has been observed [83].
3. Factors Impacting the Functional Avidity at
the Population Level
The overall functional avidity of a heterogeneous oligoclonal
T-cell population that forms during an infection [84–88] is
primarily impacted by the ratio of recruited clones with high
versus low functional avidity. Thus, the stimulatory potency
and the range of functional avidity that antigen-presenting
cells [APC] recruit during an immune response strongly
impact the avidity of the emerging T-cell population.
Whether or not an APC is able to recruit not only T cells with
high but also low functional avidity is critically impacted by
the net level of costimulatory and inhibitory molecules, but
also by the magnitude of antigen presentation.
3.1. Impact of Costimulatory and Inhibitory Molecules. The
interaction between T cells and DC involves several molec-
ular contacts between not only costimulatory but also
inhibitory molecules. Expression levels of these molecules
can modulate the T-cell activation threshold which in
turn impacts the functional avidity of the emerging T-cell
population; that is, if the threshold is for a particular reason
very high, then only T-cell clones which have a rather high
functional avidity will be activated and the overall functional
avidity of the merging population will be high.
An example for the modulation of T-cell activation
thresholds is the CD70/CD27 mediated costimulation which
enhances the response to low-aﬃnity ligands [89]. Moreover,
it has been shown that APCs which express higher levels
of B7.1, but also ICAM and LFA3, induce T cells with
higher functional avidity. Those were shown to proliferate
more vigorously, produce more cytokines, and kill target
cells more eﬃciently in both primary and secondary T-cell
responses [90, 91]. Similar observations were made using a
combination of B7 costimulations and α-CTLA-4 anti-body-
mediated blockade [92].
On the other hand, APCs can express molecules that
induce negative signals in CD8 T cells such as PD-L1. The
expression of such inhibitory receptors is mostly driven
by persisting antigen stimulation in chronic infections or
tumors [93, 94].
3.2. Antigen Doses and Antigen Presentation. Several in vitro
and in vivo studies indicate that antigen exposure influences
the antigen sensitivity of the emerging T-cell population
[95–97]. It was shown that CD8 T cells expanded by low
doses of peptide successfully lyse target cells expressing
less antigen and mediated increased viral clearance than
CD8 T cells stimulated with high peptide doses [97].
DC presenting diﬀerent densities of pMHC-complexes had
distinct influence on the functional avidity of responding
CD8 T cells in immunized mice. In particular, low antigen
doses were associated with high avidity and higher capacity
of recall responses to recognize melanoma cells [96]. Thus,
the ligand density that is presented during an infection and
during T-cell priming can impact what types of T cells
emerge [40], which seems to be particularly important in the
context of vaccination [97].
The amount of pMHC-complexes presented by an APC
critically depends on the stability of the individual pMHC-
complex. Surface pMHC-turnover rates also impact which
types of T-cell clones become activated [98, 99]. Interestingly,
DCs seem to be able to present pMHC-complexes much
longer than other cells, which likely supports their nonre-
dundant role in initiating T-cell responses [100].
More recently, the impact of the peptide dose on CD8
T-cell avidity has been investigated in melanoma patients
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vaccinated with diﬀerent doses ofMelan-A/MART-1 peptide.
Melan-A-specific CD8 T cells from patients vaccinated with
low peptide doses had functionally high-avidity T cells with
low CD8 dependency. In particular, they showed enhanced
degranulation and cytotoxic activities and lower levels of
CD8 expression [101]. These observations facilitated the
development of new immunotherapy approaches against
cancer and chronic infections.
4. Functional Avidity Maturation
The functional avidity of a T-cell population often increases
during the course of an immune response and following
pathogen reexposure [102]. Along with that, enhancement
in pMHC-multimer binding has been reported [103]. Two
principle mechanisms have been shown to contribute to the
avidity maturation phenomenon. Clonal remodeling in the
population of antigen-specific T cells occurs massively in
primary infections [104], recall responses [105, 106], and
for instance during persisting infection like CMV in humans
[107]. During this remodeling, the progeny of T-cell clones
with high functional avidity become more prevalent. In pri-
mary infections, the diﬀerences in expansion length between
T-cell clones with high or low functional avidity account for
this phenomenon [104]. However, the mechanisms driving
clonal remodeling in secondary infections are less clear, but
it is likely caused by antigen competition between high and
low-aﬃnity T cells clones [108] and possibly by alterations in
the T-cell stimulation threshold.
Moreover, several lines of evidence suggest that even
T cells expressing the same TCR can diﬀer in their func-
tional avidity and that the latter depends on the state of
diﬀerentiation of T cells. For instance, it has been shown
that during an LCMV infection, the functional avidity of
TCR transgenic T cells increases [81]. Moreover, it has
been observed that memory T cells can exhibit a higher
functional avidity than that of naı¨ve T cells [109, 110].
Several mechanisms have been proposed to contribute to
the maturation of the functional T-cell avidity at the clonal
T-cell level. Those include (1) the formation of clusters
that comprise several TCRs and other molecules able to
reinforce the immunological synapses and changes in the
cholesterol content of the membrane contribute to such
diﬀerences [111–113] and (2) the optimization of the signal
transduction machinery, for example, by increasing the
amount and the basal phosphorylation levels of signaling
molecules [81, 114]. Moreover, it has been shown that the
expression of Lck correlates with the production of IFN-γ,
whereby minor increases in Lck expression lead to major
increases in IFN-γ production [57]. In contrast, it has also
been reported that the functional avidity can decrease [65]
or remain similar (as seen for OT-1 TCR transgenic T cells
[104]) during an infection, and whether or not memory
T cells are truly more sensitive than naı¨ve T cells remains
controversial.
Overall, functional avidity maturation allows faster virus
clearance/control at the time of antigen reencounter and a
progressive acquisition of coreceptor binding and costim-
ulatory signal independency [81, 115, 116]. In the context
of peripheral tolerance, however, the continuous exposure
to antigen in the context of molecular mimicry might
lead to aﬃnity maturation which in turn may result in
autoimmunity [72]. Besides this consideration, it has also
been shown that autoreactive T cells undergo limited avidity
maturation [117].
In contrast to these processes that follow acute infection,
the dynamics in the T-cell population in chronic infections
appear to be diﬀerent. We recently demonstrated that HIV-
specific CD8 T cells undergo a massive TCR renewal for
instance following a virus rebound [84]. Interestingly, it has
been observed that changes in TRBV populations overtime
go along with a loss of low-avidity T cells clones or more
generally speaking an increase in functional avidity [118].
These observations will be discussed in more details in the
final sections of this paper.
5. The Functional Avidity of T Cells as
a Correlate of Immune Protection
There is a general consensus that higher functional avidity
CD8 T-cell responses are of higher eﬃcacy to eliminate
cancer cells and to clear acute virus infections, a notion that is
supported by a large number of reports [103, 106, 119–121].
It was for instance shown that high functional avidity
Tax-specific CD8 T-cell lines—which use a very diverse
TCR repertoire—are superior in their ability to eliminate
HTLV-1-infected cells than low-avidity Tax-specific CD8 T
cells. These cells were also able to recognize a latent Tax
level (detectable only by RT-PCR) produced by adult T-cell
leukemia cells (ATLs), thus possibly leading to the prevention
of HTLV-1 infection [122].
For tumors, high functional avidity T cells mediate better
T-cell responses [119], though it needs to be said that
tolerance-enforcing mechanisms eﬀectively remove high-
avidity self- and tumor-antigen reactive T cells [123, 124].
Thus, tumor-reactive T cells will in most cases have a lower
functional avidity than what can be observed during acute
infections.
Low antigen expression and absence of inflammatory
and costimulatory signals may be partially responsible for
the low immunogenicity of many tumor cells. The presence
of higher-avidity CD8 T cells may be particularly relevant
to overcome the tolerance to tumor antigens. This may be
achieved by defining a combination of adjuvants and by
regulating antigen doses in vaccines [97, 125, 126]. Indeed,
higher-avidity T cells are preferentially triggered leading to
a more rapid and eﬀective target-cell elimination [14, 26,
97, 119, 127–129]. Consistently, in both humans and mice
models, induction of higher-avidity CD8 T-cell responses
promoted more eﬃcient tumor rejection [101, 130] and
earlier target cell lysis in the context of viral infection,
reducing viral burden more eﬀectively than low-avidity CD8
T cells. In addition, this activity does not depend on the
frequency of antigen-specific CD8 T cells [131].
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There are also several studies correlating the presence
of certain MHC alleles with diﬀerences in the diversity
and functional avidity of T-cell clones that emerge during
tumors or chronic infections. For example, H-2Kbm8 mice
express an H-2K allele that diﬀers in four amino acids from
H-2Kb. Compared to C57BL/6 mice, the H-2Kbm8 mice
generate a diﬀerent repertoire of high-avidity herpes simplex
virus- (HSV-) specific T cells which correlates with a higher
resistance to HSV infection [14].
Similarly, C57BL/6 mice are less susceptible to respiratory
syncytial virus (RSV) infection than BALB/c mice. Among
the many possible explanations, it has been observed that
the H-2d alleles induce the generation of immunodominant
antigen-specific CD8 T-cell populations that use a more
restricted TCR repertoire, and that is less eﬃcient in lysing
target cells than what can be observed in C57BL/6 mice. This
results in continuous T-cell stimulation and thus in cytokine-
mediated immunopathology [132].
Furthermore, the strongest genetic association of the
ability to eﬀectively control HIV infections points at the
MHC locus [32] and at the presence of certain MHC
molecules such as HLA-B∗57 [133]. In line with the earlier
mentioned, the latter is thought to strongly impact the
repertoire and the quality of HIV-specific T cells and thus
enabling an enhanced virus control.
In contrast to these observations, the relevance of high-
and low-avidity T cells in chronic virus infections and
established tumors [86, 134, 135] remains to be deter-
mined, in particular, since some studies have challenged the
superiority of high-avidity CD8 T cells [136, 137]. Indeed,
low-avidity T cells (1) might better distinguish between
tumors overexpressing self-antigens and healthy self-tissue
[136] and (2) might during chronic viral infections and
tumors be less sensitive to activation-induced cell death
(AICD) [129, 138], senescence and exhaustion, leading to
protracted survival of functionally-competent T cells, and
(3) are less likely to induce viral or tumor escape [26, 134,
139].
In the context of chronic-controlled infections, such as
CMV and EBV, the T-cell responses to immunodominant
antigens have a more diverse repertoire with higher TCR
avidity than that of subdominant clonotypes. However, they
are also more prone to senescence [140]. In addition, in
vitro stimulation at high antigen concentrations induces
higher AICD [138] and more pronounced inhibition of
proliferation in high-avidity than in low-avidity T cells
[129]. Finally, we [36] and others [141] have shown that
high-avidity CD8 T cells express higher levels of the T-cell
exhaustion marker PD-1 than those of low-avidity CD8 T
cells.
In addition, in the context of tumor immunity, skin
depigmentation is considered as a good prognosis indicator
in melanoma patients, since it is a sign of immune activation
against tumor/self-antigens, and a high frequency of CD8
T cells was observed in depigmentated tissue from patients
[137]. These were MC1R HLA-A2-specific, and despite
harboring low functional avidity, they were cytolytic and
produced IFN-γ and granzyme B [137]. Interestingly, immu-
nization of mice tolerant to the hemagglutinin (HA) antigen
and bearing a renal carcinoma overexpressing HA led to
the expansion of low-avidity HA-specific CD8 T cells. These
could only target tumor cells expressing high antigen doses,
thus allowing the destruction of HA-over-expressing tumors
but not healthy pancreatic cells [136].
However, it is worth mentioning that depending on the
biology of the pathogen, T cells endowed with diﬀerent func-
tions and tropism are required, and, thus, a generalization
of the features of a universally eﬃcient T-cell response is
complicated or may be not possible.
6. Functional Avidity as a Correlate of
Control in HIV Infection
With regard to HIV infection, contrasting conclusions on
the relationship between functional avidity and virus control
have been reported [142–146]. Some studies indicated that
protective HIV-specific CD8 T-cell responses (e.g., those
observed inHIV-infected patients with nonprogressive infec-
tion) were of high functional avidity and mediated superior
variants recognition [86, 135, 143, 147, 148]. In these
studies, high-avidity CD8 T cells were not only mostly poly-
functional, endowed with potent virus suppressive activity,
increased cross-reactivity, and associated with low levels of
virus replication [86, 135, 147], but were also characterized
by an increased T-cell turnover and senescence [86].
However, most of these studies focused on HIV-specific
CD8 T-cell responses directed against only one epitope, and
analyses were performed on single clones derived from T-
cell expansion which may not reflect the in vivo/ex vivo
profile of T cells [38, 39]. In addition, since the majority of
studies reporting correlations between functional avidity and
virus control are cross-sectional and not prospective studies
in unselected populations, it is not possible to determine
causality between avidity and virus control.
More recently, it was shown that gag-specific and HLA-
B-restricted CD8 T-cell responses, usually associated with
virus control [16, 149], have higher functional avidity than
nef-, pol-, and env-specific CD8 T-cell responses [147].
Also, both gag-specific and HLA-B-restricted CD8 T-cell
responses were of higher functional avidity in controllers
than in noncontrollers. Finally, consistently with the above-
mentioned studies, protective T-cell responses against KK10
and KF11 (restricted by HLA-B∗2705 and B∗5701, resp.) had
higher functional avidity than all the other HLA-B-restricted
epitopes [147].
Conversely, other studies indicated that the functional
avidity of HIV-specific CD8 T cells is not diﬀerent between
patients with progressive or nonprogressive chronic infec-
tion or between gag- and other HIV-specific CD8 T cells
[150] and also that uncontrolled virus replication seen
in progressive HIV infection occurs despite the presence
of high-avidity HIV-specific CD8 T-cell responses [142–
146, 151, 152]. In this regard, we previously showed that
polyfunctional virus-specific CD8 T-cell responses in the
context of chronic viral infections were predominantly of
low functional avidity [36]. In addition, when the avidity of
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two diﬀerent CD8 T-cell clonotypes recognizing one HLA-
B∗35-restricted Pol epitope was analyzed, a 3fold diﬀerence
in t1/2 for HLA-multimer interaction was found. In contrast
to the clone of lower aﬃnity, the one with higher aﬃnity
did not show cytotoxic activity, cytokine production, or
proliferative capacity following stimulation with the cognate
antigen [153]. Furthermore, CD8 T cells transduced with a
high-aﬃnity TCR showed greater binding activity toward the
specific multimer, but impaired cytotoxicity [153].
Finally, it was also reported that high functional avidity
T-cell responses preferentially led to viral escape, T-cell
clonal exhaustion, and senescence [26, 86, 134, 139, 141,
154]. Indeed, CD8 T cells have distinct ability to select
for escape mutations for the same epitope depending on
HLA restriction. The HLA restriction which confers higher
avidity for the epitope induces a substantially higher level of
sequence variation and clonal turnover which in turn leads to
faster viral escape [134] and T-cell senescence [86]. However,
to some extent, the emergence of viral variants escaping
recognition from higher avidity T-cell responses may also be
interpreted as an argument to support the eﬃcacy of high-
avidity T cells against HIV. Furthermore, the specificity of
CD8 T-cell responses is critical, since cells directed toward
highly variable regions may nonetheless not be able to
mediate virus control. In case, they might only cause the
emergence of virus escape variants. Moreover, TCR avidity
correlates with PD-1 expression levels, and, consistently,
high-avidity CD8 T cells displayed an impaired survival
in in vitro culture at low levels of antigen stimulation. In
vivo, subdominant clonotypes not only are of low functional
avidity and express lower PD-1 levels than those of dominant
clonotypes, but also respond more eﬃciently to variant epi-
topes, thus displaying a greater capacity of cross-recognition
[141]. Although increased PD-1 expression might also be
interpreted as a marker of increased activation of higher
avidity T cells [155], in the context of chronic infection such
as HIV, PD-1 is predominantly considered as a marker of
exhausted cells [156].
Although large-scale longitudinal studies are needed
to further elucidate the dynamic relationships between
functional avidity, immunodominance, and viral escape, the
aforementioned information suggest that lower functional
avidity T-cell responses might be more suitable in the context
of HIV infection.
7. Functional Avidity of T Cells in
Acute HIV Infection
A better understanding of the immune response during
primary HIV infection (PHI) is of particular relevance, since
HIV-specific CD8 T cells in PHI are temporally associated
with the initial control of virus replication [2].
Of interest, Lichterfeld and colleagues suggested that
high-avidity HIV-specific CD8 T-cell responses are present
during early infection (defined as HIV seroconversion within
6 months) but are then selectively depleted overtime [118].
To our knowledge, there is no previous study addressing the
issue of the functional avidity of HIV-specific CD8-T cells
in a cohort of HIV-infected patients with very early acute
infection (based on stringent criteria of enrollment).
However, we recently had the opportunity to investigate
the functional avidity of HIV-specific CD8 T-cell responses
in a true PHI cohort (i.e., presence of an acute clinical
syndrome, a negative HIV antibody test, a positive test for
HIV RNA in plasma, and presence of fewer than three
positive bands in a Western blot) [157]. In this context,
we observed that the functional avidity of HIV-specific
CD8 T-cell responses was significantly lower in PHI than
in chronic infection and remained low after several years
of antiretroviral therapy (Vigano and Harari, unpublished
observation). Conversely, we noted (Figure 2) an increase
in the functional avidity of HIV-specific CD8 T cells in
patients experiencing a virus rebound following treatment
interruption [84].
These observations might be explained by two nonmu-
tually exclusive mechanisms: first, the progressive selection
of clones with higher functional avidity and, on the other
hand, the recruitment of new clones with higher functional
avidity. The potential combination of these mechanisms
would induce a modification of the TCR repertoire [84, 103,
106, 107, 118].
8. Perspectives and Hypothesis
Detailed monitoring of phenotypes and functional charac-
teristics of T cells in diﬀerent viral infection has strongly
augmented our understanding of the relationship between
viral infections and the immune response they induce. We
recently made thorough comparisons of the types of T cells
responding to infections that the immune system rapidly
clears (Influenza (Flu) or Adenovirus (Ad5)), or infections
caused by CMV and EBV as well as HIV infections in
the acute and chronic phase. We saw that the functional
avidity of T cells specific to Flu and Ad5 was similar to
that of T cells in the acute phase of HIV infection. In
contrast, significantly higher functional avidities of T cells
were noticed in the chronic progressive and nonprogressive
HIV infection, but interestingly those were comparable to
the functional avidity seen during chronic CMV and EBV
infections. Furthermore, when patients were treated during
acute infection but experienced a virus rebound following
treatment interruption (TI), the functional avidity of HIV-
specific CD8 T cells increased (AH and SV unpublished
observations).
9. Summary
Functional T-cell avidity is a critical attribute of antiviral and
antitumoral immunity. The strength of interaction between
the TCR and pMHC-molecule, expression levels of the
coreceptors, as well as signaling particularities are pivotal in
determining the functional avidity of a T-cell clone.
It is well established that T-cell populations can over
the course of infection or upon multiple exposure to
infections or infectious exacerbation undergo significant
changes in the ability to recognize cognate antigen. The
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Figure 2: ProposedModel of the relationships between antigen exposure and functional avidity of T cells. Functional avidity of virus-specific
CD8 T cells during (a) acute infection and then translation after transition to the chronic phase for (b) uncontrolled virus infection (such as
progressive HIV infection) or (c) controlled but persistent virus infection (such as nonprogressive HIV, cytomegalovirus [CMV], or Epstein-
Barr virus [EBV], or (d) after virus clearance (such as influenza [Flu] or adenovirus [Ad5], or early treatment of acute HIV infection). (e)
Increase in the functional avidity of HIV-specific CD8 T cells of patients treated during acute infection who interrupted the antiretroviral
therapy [TI] and experienced a virus rebound.
later is at a first glance somewhat surprising as T cells,
unlike B cells, express a fixed TCR and cannot undergo
somatic hypermutation. Predominantly, the clonal compo-
sition impacts the functional avidity of the T-cell population
and avidity maturation. In addition to the reinforcement of
the immunological synapses through the formation of TCR
clusters, the optimization of the signal transduction machin-
ery further contributes to avidity maturation. However, the
understanding of mechanisms underlying this phenomenon
is still limited, and further studies need to be undertaken to
better understand how all these possible variations and likely
many yet unknown ones impact the functional avidity of T
cells when responding to diﬀerent types of infections.
In the context of viral infections, functional avidity
maturation allows faster virus clearance by recall T-cell
responses. However, the role of high versus low functional
avidity T cells in chronic viral infections such as HIV remains
unclear. Here, it needs to be considered that high-avidity
T cells exhibit greater T-cell exhaustion and lead to rapid
emergence of escape variants suggesting a pivotal role of low-
avidity T cells.
Studies to better delineate the factors influencing the
functional avidity of T-cell responses are relevant in order
to allow fine tuning of the profile of vaccine-induced T cells.
We consider that the goal of vaccination or immunotherapy
against acute infections and to induce pathogen clearance
should be the induction of high-avidity T cells, since such
cells most eﬀectively eliminate infected cells. Conversely,
when pathogen clearance cannot be achieved, then the
ultimate goal is to provide durable control of a persistent
pathogen. A vaccine that deals with such a situation should
be designed to generate low-avidity T cells, since those might
be more suitable to generate a pool of long-lasting eﬀector T
cells in a situation of chronic infection.
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